Use of artificial intelligence (AI) applications is growing rapidly in clinical trials and drug development, with new initiatives, opportunities and approaches cropping up almost weekly. Following are brief profiles of two of the latest AI developments in the clinical trial space.

Massive Bio and Perthera.ai, an oncology intelligence company, have teamed up to help improve cancer trial enrollment. The pair will put both of their AI-fueled solutions together in this endeavor to connect cancer patients with clinical research opportunities and offer personalized therapy recommendations.

“By combining Perthera.ai’s focus on biomarker-based algorithms with our AI-powered clinical trial matching platform, we can create more options for patients and physicians to find the best trials,” said Selin Kurnaz, co-founder and CEO of Massive Bio. “We can also pursue additional innovations together around real-world data, biomarker discovery, and diagnostic and commercial collaborations with industry stakeholders.”

Alimentiv, Satisfai Health and Virgo are also utilizing AI in clinical research, unveiling a three-way partnership “to revolutionize central reading, data capture, decision support and patient recruitment” in inflammatory bowel disease and gastrointestinal (GI) disease trials.

Alimentiv, a CRO, describes itself as a “niche GI contract research organization” working in inflammatory bowel disease, eosinophilic gastrointestinal disorders and nonalcoholic steatohepatitis. Its partners, Satisfai and Virgo, develop solutions for gastroenterology and endoscopy video capture, respectively.